Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03053440




Registration number
NCT03053440
Ethics application status
Date submitted
7/02/2017
Date registered
15/02/2017
Date last updated
26/10/2024

Titles & IDs
Public title
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
Scientific title
A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)
Secondary ID [1] 0 0
2016-002980-33
Secondary ID [2] 0 0
BGB-3111-302
Universal Trial Number (UTN)
Trial acronym
ASPEN
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Waldenström's Macroglobulinemia 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Cancer 0 0 0 0
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Cancer 0 0 0 0
Children's - Leukaemia & Lymphoma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BGB-3111
Treatment: Drugs - Ibrutinib

Experimental: Arm A : Ibrutinib - Participants with the MYD88 mutation received Ibrutinib

Active comparator: Arm B: Zanubrutinib - Participants with the MYD88 mutation received zanubrutinib


Treatment: Drugs: BGB-3111
160 mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor

Treatment: Drugs: Ibrutinib
420 mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Achieving Either a Complete Response (CR) or Very Good Partial Response (VGPR) Using an Adaptation of the Response Criteria Updated at the Sixth International Workshop on WM as Assessed by an Independent Review Committee (IRC)
Timepoint [1] 0 0
Up to approximately 2 years and 7 months
Secondary outcome [1] 0 0
Percentage of Participants Achieving Major Response Rate (MRR) as Assessed by IRC
Timepoint [1] 0 0
Up to approximately 2 years and 7 months
Secondary outcome [2] 0 0
Duration of Response (DOR) as Assessed by IRC
Timepoint [2] 0 0
Up to approximately 2 years and 7 months
Secondary outcome [3] 0 0
DOR as Assessed by IRC: Event -Free Rate
Timepoint [3] 0 0
12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
Secondary outcome [4] 0 0
Percentage of Participants Achieving Either CR or VGPR in as Assessed by the Investigator
Timepoint [4] 0 0
Up to approximately 5 years and 5 months
Secondary outcome [5] 0 0
DOR as Assessed by the Investigator
Timepoint [5] 0 0
Up to approximately 5 years and 5 months
Secondary outcome [6] 0 0
DOR as Assessed by the Investigator: Event-Free Rate
Timepoint [6] 0 0
24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
Secondary outcome [7] 0 0
Progression Free Survival (PFS) as Assessed by the IRC
Timepoint [7] 0 0
Up to approximately 2 years and 7 months
Secondary outcome [8] 0 0
PFS as Assessed by IRC: Event-Free Rate
Timepoint [8] 0 0
12 and 18 months from the date of randomization (up to approximately 2 years and 7 months)
Secondary outcome [9] 0 0
PFS as Assessed by the Investigator
Timepoint [9] 0 0
Up to approximately 5 years and 5 months
Secondary outcome [10] 0 0
PFS as Assessed by the Investigator: Event-Free Rate
Timepoint [10] 0 0
24,36 and 48 months from the date of randomization (up to approximately 5 years and 5 months)
Secondary outcome [11] 0 0
Percentage of Participants With Resolution of All Treatment-precipitating Symptoms
Timepoint [11] 0 0
Up to approximately 5 years and 5 months
Secondary outcome [12] 0 0
Percentage of Participants With an Anti-Lymphoma Effect
Timepoint [12] 0 0
Up to approximately 5 years and 5 months
Secondary outcome [13] 0 0
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Timepoint [13] 0 0
Up to approximately 5 years and 5 months

Eligibility
Key inclusion criteria
Key

* Clinical and definitive histologic diagnosis of WM
* Measurable disease, requiring treatment
* Participants with no prior therapy for WM, must be considered inappropriate candidates for treatment with a standard chemoimmunotherapy regimen
* Age = 18 years old
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
* Adequate bone marrow function
* Adequate renal and hepatic function
* Electrocardiogram/multigated acquisition scan (ECHO/MUGA) demonstrating left ventricular ejection fraction (LVEF)= the lower limit of institutional normal
* Participants may be enrolled who relapse after autologous stem cell transplant if they are at least 3 months after transplant, and after allogeneic transplant if they are at least 6 months post-transplant.
* Females of childbearing potential must agree to use highly effective forms of birth control throughout the course of the study and at least up to 90 days after last dose of study drug. Males must have undergone sterilization- vasectomy, or utilize a barrier method
* Life expectancy of > 4 months

Key
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior exposure to a BTK inhibitor
* Evidence of disease transformation at the time of study entry
* Corticosteroids given with antineoplastic intent within 7 days, or chemotherapy given with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapy within 4 weeks of the start of study drug
* Major surgery within 4 weeks of study treatment
* Toxicity of = Grade 2 from prior anticancer therapy
* History of other active malignancies within 2 years of study entry, with exception of (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally with curative intent
* Currently active, clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease within 6 months of screening
* QTcF prolongation (defined as a QTcF > 480 msec)
* Active, clinically significant Electrocardiogram (ECG) abnormalities
* Unable to swallow capsules or disease significantly affecting gastrointestinal function such as malabsorption syndrome, resection of the stomach or small bowel, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
* Uncontrolled active systemic infection or recent infection requiring parenteral anti-microbial therapy
* Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C
* Pregnant or lactating women
* Any life-threatening illness, medical condition, organ system dysfunction, need for profound anticoagulation, or bleeding disorder, which, in the investigator's opinion, could compromise the subject's safety
* Any medications which are strong or moderate cytochrome P450, family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/01/2017
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
21/06/2022
Sample size
Target
Accrual to date
Final
201
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Paratus Clinical Research Woden - Canberra
Recruitment hospital [2] 0 0
St George Hospital - Kogarah
Recruitment hospital [3] 0 0
Royal North Shore Hospital - St Leonards
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [5] 0 0
Flinders Medical Centre - Bedford PK
Recruitment hospital [6] 0 0
Monash Health - Clayton
Recruitment hospital [7] 0 0
St Vincents Hospital Melbourne - Fitzroy
Recruitment hospital [8] 0 0
Peninsula Health Frankston - Frankston
Recruitment hospital [9] 0 0
Barwon Health the Geelong Hospital - Geelong
Recruitment hospital [10] 0 0
Peter Maccallum Cancer Centre - Melbourne
Recruitment hospital [11] 0 0
Sir Charles Gairdner Hospital - Nedlands
Recruitment postcode(s) [1] 0 0
2606 - Canberra
Recruitment postcode(s) [2] 0 0
2217 - Kogarah
Recruitment postcode(s) [3] 0 0
2065 - St Leonards
Recruitment postcode(s) [4] 0 0
4102 - Brisbane
Recruitment postcode(s) [5] 0 0
5042 - Bedford PK
Recruitment postcode(s) [6] 0 0
3168 - Clayton
Recruitment postcode(s) [7] 0 0
3065 - Fitzroy
Recruitment postcode(s) [8] 0 0
3199 - Frankston
Recruitment postcode(s) [9] 0 0
3220 - Geelong
Recruitment postcode(s) [10] 0 0
3000 - Melbourne
Recruitment postcode(s) [11] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Massachusetts
Country [5] 0 0
United States of America
State/province [5] 0 0
Minnesota
Country [6] 0 0
United States of America
State/province [6] 0 0
Tennessee
Country [7] 0 0
United States of America
State/province [7] 0 0
Washington
Country [8] 0 0
Czechia
State/province [8] 0 0
Hradec Kralove
Country [9] 0 0
Czechia
State/province [9] 0 0
Ostrava
Country [10] 0 0
Czechia
State/province [10] 0 0
Praha
Country [11] 0 0
France
State/province [11] 0 0
Lyon Cedex
Country [12] 0 0
Germany
State/province [12] 0 0
Sigmaringen
Country [13] 0 0
Germany
State/province [13] 0 0
Ulm
Country [14] 0 0
Greece
State/province [14] 0 0
Athens
Country [15] 0 0
Italy
State/province [15] 0 0
Bologna
Country [16] 0 0
Italy
State/province [16] 0 0
Brescia
Country [17] 0 0
Italy
State/province [17] 0 0
Meldola
Country [18] 0 0
Italy
State/province [18] 0 0
Milano
Country [19] 0 0
Italy
State/province [19] 0 0
Novara
Country [20] 0 0
Italy
State/province [20] 0 0
Pavia
Country [21] 0 0
Italy
State/province [21] 0 0
Ravenna
Country [22] 0 0
Italy
State/province [22] 0 0
Roma
Country [23] 0 0
Italy
State/province [23] 0 0
Torino
Country [24] 0 0
Italy
State/province [24] 0 0
Udine
Country [25] 0 0
Netherlands
State/province [25] 0 0
Amsterdam
Country [26] 0 0
Netherlands
State/province [26] 0 0
Utrecht
Country [27] 0 0
Poland
State/province [27] 0 0
Bialystok
Country [28] 0 0
Poland
State/province [28] 0 0
Brzozow
Country [29] 0 0
Poland
State/province [29] 0 0
Bydgoszcz
Country [30] 0 0
Poland
State/province [30] 0 0
Chorzow
Country [31] 0 0
Poland
State/province [31] 0 0
Krakow
Country [32] 0 0
Spain
State/province [32] 0 0
Badalona
Country [33] 0 0
Spain
State/province [33] 0 0
Barcelona
Country [34] 0 0
Spain
State/province [34] 0 0
Madrid
Country [35] 0 0
Spain
State/province [35] 0 0
Salamanca
Country [36] 0 0
Spain
State/province [36] 0 0
Valencia
Country [37] 0 0
Sweden
State/province [37] 0 0
Stockholm
Country [38] 0 0
United Kingdom
State/province [38] 0 0
Bournemouth
Country [39] 0 0
United Kingdom
State/province [39] 0 0
Headington
Country [40] 0 0
United Kingdom
State/province [40] 0 0
Leeds
Country [41] 0 0
United Kingdom
State/province [41] 0 0
London
Country [42] 0 0
United Kingdom
State/province [42] 0 0
Nottingham
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Plymouth

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study evaluated the safety, efficacy and clinical benefit of BGB-3111 (zanubrutinib) vs ibrutinib in participants with MYD88 Mutation Waldenström's Macroglobulinemia.
Trial website
https://clinicaltrials.gov/study/NCT03053440
Trial related presentations / publications
Tam CS, LeBlond V, Novotny W, Owen RG, Tedeschi A, Atwal S, Cohen A, Huang J, Buske C. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenstrom macroglobulinemia. Future Oncol. 2018 Sep;14(22):2229-2237. doi: 10.2217/fon-2018-0163. Epub 2018 Jun 5.
Public notes

Contacts
Principal investigator
Name 0 0
Study Director
Address 0 0
BeiGene
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03053440